Navigation Links
GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission
Date:10/3/2011

SEATTLE, Oct. 3, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals Hamilton has donated a broad range of instrumentation and equipment that will assist IDRI as it designs and validates solutions to reduce the burden of disease in the developing world. IDRI will apply the gift as it prepares for clinical trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza.

"We at IDRI view this generous gift by our friends at GSK as a demonstration of confidence that the products IDRI is researching today will soon be making a difference for people worldwide," said H. Stewart Parker, IDRI's Chief Executive Officer.  "GSK's generous donation will enable new health technologies to be deployed for a number of diseases that particularly affect those in low resource settings."

"GSK has seen IDRI's talented scientists develop world-class technologies that have entered into numerous successful clinical trials," said Pamela Sager, Business Support Manager at GSK.  "We believe that the equipment we are giving to IDRI will not only further the world's scientific understanding of infectious diseases, but that this gift will also advance IDRI's global health mission."

GSK acquired the equipment when the company purchased the former Corixa site in Seattle in 2005.

About IDRI
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.
IDRI Contact: media@idri.org, 206-381-0883

About GSK
GlaxoSmithKline:  A Leader in Vaccines
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation.   The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing around the world and 20 more in development.

For more information, go to www.gsk.com.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results
2. GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older
3. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
4. GlaxoSmithKline Confirms allis Safety Profile
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. GlaxoSmithKline Wins Environmental Stewardship Award
7. GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits
8. GlaxoSmithKline Applauds North Carolinas Child Advocates
9. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
10. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
11. GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Visiomed, the French ... since 1997, is changing the landscape of healthcare ... patients with pro-active, custom-made solutions. Recognizing the rising ... and affordable healthcare without walls, Visiomed has launched ... developed with healthcare professionals that is empowering the ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... , ... Current Meditation , a new meditation concept ... U.S. starting this spring. Current Meditation focuses on “meditation for the modern world,” ... will be the first meditation concept in the U.S. offering franchising opportunities, setting ...
(Date:2/23/2017)... ... (PRWEB) ... opportunity for the nation to come together to combine its ... – with its favorite fruit – apples! To celebrate National ... to join the “Apple Madness” bracket tournament – a five-week, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez has lived ... continued to spiritually evolve, which is the purpose of everyone in this universe. As ... ” (published by Balboa Press) attempts to guide readers to expand one’s spiritual life. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company that ... its products are coming soon to Amazon.com, the world’s largest online retailer. ... means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been ...
Breaking Medicine News(10 mins):